iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/20445061/
Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 5;30(18):6355-9.
doi: 10.1523/JNEUROSCI.6119-09.2010.

Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains

Ahmad Jowaed  1 , Ina Schmitt, Oliver Kaut, Ullrich Wüllner
Affiliations

Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains

Ahmad Jowaed et al. J Neurosci. .

Abstract

Alpha-synuclein (SNCA) is a major risk gene for Parkinson's disease (PD), and increased SNCA gene dosage results in a parkinsonian syndrome in affected families. We found that methylation of human SNCA intron 1 decreased gene expression, while inhibition of DNA methylation activated SNCA expression. Methylation of SNCA intron 1 was reduced in DNA from sporadic PD patients' substantia nigra, putamen, and cortex, pointing toward a yet unappreciated epigenetic regulation of SNCA expression in PD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The SNCA region of interest. a, Schematic drawing of the 5′ region of SNCA with exons 1 and 2 (boxes) and the 5′ UTR and intron 1 (line). The arrow indicates the position of the putative core promoter; the triangle indicates the position of a rudimentary TATA box. Dimension of the CGI is depicted by the stripped box. Numbers are relative to the translation start site (ATG + 1). b, Fragments SNCA(−2079/−1507) (promoter) and SNCA(−926/−483) (intron) were used for bisulfite sequencing. c, Fragment SNCA(−1524/−189) was used for reporter assays. d, Predicted transcription factor binding sites within SNCA(−926/−483) (intron) adjacent to CpG dinucleotides.
Figure 2.
Figure 2.
Status of SNCA methylation in SK-N-SH cells and impact on expression. a, SK-N-SH cells were incubated with DMSO [control (Ctrl)] or 10 μm Aza for 24 and 48 h, respectively, and isolated DNA was used for bisulfite sequencing of SNCA(−2079/−1507) (promoter) and SNCA(−926/−483) (intron); 10 independent clones for each condition were analyzed by bisulfite sequencing. The lollipop diagram with unmethylated CpG sites (open circles) and methylated CpG sites (closed circles) illustrates the higher degree of methylation in SNCA(−926/−483) (intron) compared with SNCA(−2079/−1507) (promoter) and the decrease of methylated CpG in SNCA(−926/−483) (intron) after addition of Aza. b, After 48 h of Aza treatment, the fraction of methylated CpGs is reduced by ∼60% in SNCA(−926/−483) (intron). c, Treatment with Aza induced a time-dependent increase of SNCA expression exceeding 50% of Ctrl. Quantitative RT-PCR was performed in triplicate and presented as the mean ± SD. d, Representative Western blot with anti-synuclein antibody demonstrates an increase of synuclein protein after addition of Aza too.
Figure 3.
Figure 3.
Promoter activity of SNCA(−1524/−189) in HeLa cells. In vitro methylation of the reporter construct SNCA(−1524/−189) reduced relative luciferase activity by 98.5% (**p ≤ 0.01, one-way ANOVA). Absence of SssI or SAM from the in vitro methylation reaction minimized reduction. Ctrl, Construct with the inverted insert.
Figure 4.
Figure 4.
Status of SNCA(−926/−483) methylation in human brain. a, Mean percentages (±SD) of methylated CpG sites summed up over all 23 CpG sites analyzed. PD patients' DNA was hypomethylated compared with the neurologically healthy individuals in all analyzed brain regions. *p ≤ 0.05, **p ≤ 0.01. b, Detailed comparison of the methylation of SNCA(−926/−483) in DNA from SNpc, putamen, and cortex of PD and neurologically healthy individuals. Percentage of methylated CpG at the particular position in the three different brain regions. Asterisks indicate significant (p ≤ 0.05, one-way ANOVA) hypomethylation in PD patients compared with control (mean ± SD of at least 10 clones per individual per CpG position analyzed by bisulfite sequencing).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211. - PubMed
    1. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422–437. - PubMed
    1. Chiba-Falek O, Lopez GJ, Nussbaum RL. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord. 2006;21:1703–1708. - PubMed
    1. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Padbury JF, Bueno R, Sugarbaker DJ, Yeh RF, Wiencke JK, Kelsey KT. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet. 2009;5:e1000602. - PMC - PubMed
    1. Clough RL, Stefanis L. A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J. 2007;21:596–607. - PubMed

Publication types